Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $235.35. The company's market cap stands at 34.78B, with a P/E ratio of 41.23.
On 2026-10-16, Biogen(BIIB) stock opened at $236.48, reached a high of —, and a low of —.
Biogen(BIIB) shares are trading with a volume of 0, against a daily average of 1.22M.
During the past year, Biogen(BIIB) stock moved between $138.00 at its lowest and $240.99 at its peak.
During the past year, Biogen(BIIB) stock moved between $138.00 at its lowest and $240.99 at its peak.
BIIB News
...
Biogen reported 52 week Phase 2 data from the AMETHYST trial of litifilimab in cutaneous lupus erythematosus, showing sustained skin disease improvements, a gen...
UBS raised the firm’s price target on Biogen (BIIB) to $270 from $240 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma a...
Analyst ratings
68%
of 37 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.